Company intelligence / Profile preview

Altamira Medica AG

Ownership: Private
Development stage: Preclinical

Overview

Altamira Medica AG commercializes Bentrio®, a drug-free, preservative-free nasal spray for the treatment of allergic rhinitis. Bentrio® has been cleared by the FDA and will be marketed in the US through a licensing partner. The product has achieved marketing approval in several regions and expects approval for Mainland China in 2025. In Europe, it’s transitioning to Class IIa under new MDR regulations[4].

Therapeutic areas: Immunology
Modalities: Nasal spray medical devices
Industry: Therapeutic Medical Devices

Drug pipeline

3 assets

AM-401

Pre-clinical

Indications: KRAS-driven cancers

2 more assets in the full pipeline.

Request access →

Partnerships

Distribution partners covering Southeast Asia and parts of Scandinavialicensing partner discussions ongoing for US commercialization[4]

Beyond the preview

Go deeper on Altamira Medica AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Altamira Medica AG.

Explore the full profile